A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Recruiting
Phase 2
Phase 3
Interventional Study
Hidradenitis Suppurativa (HS)
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 210 (estimated)
- Sponsor
- Bluefin Biomedicine, Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year.
* Have moderate to severe disease not well controlled by systemic antibiotic treatment.
* Are willing to follow study instructions, attend regular visits, and avoid certain other me…
Contacts